HealthTech Innovation Days #5
October 24, 2023
Paris, France
Bioxodes will be present at the 5th Edition of the HealthTech Innovation Days
We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice
Cookies settings I agree I refuseCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with an intracerebral hemorrhage (ICH).
Neuroinflammation plays a critical role in the neurologic decline of ICH patients. Ir-CPI, the lead drug candidate of this program, exhibits a unique mechanism of action by targeting coagulation factors (FXIIa & FXIa) and neutrophils, key driver components of the neuroinflammatory process. Ir-CPI prevents blood clot formation without increasing the bleeding risk — a major asset in ICH patients — due to the specific coagulation factors targeted by this compound.
In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of Ir-CPI against neutrophil activation and neutrophil extracellular trap (NET) formation.
Our innovative pipeline includes a clinical-stage program with Ir-CPI for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients. The initiation of the Phase IIa program to collect safety data and first evidence of efficacy in patients is expected early 2023.
Our first-in-class drug candidate with a unique mechanism of action on neutrophils and coagulation factors (FXIa and FXIIa).
Bioxodes is building an innovative pipeline with drug candidates for the prevention of thrombo-inflammatory and inflammatory diseases.
Clinical trials are being conducted to assess the safety and efficacy of Ir-CPI with a primary focus on hemorrhagic stroke.
HealthTech Innovation Days #5
October 24, 2023
Paris, France
Bioxodes will be present at the 5th Edition of the HealthTech Innovation Days
23rd Annual Biotech in Europe Forum - Sachs Associates
September 20, 2023
Basel, Switzerland
Bioxodes' CEO March Dechamps presents at the 23rd Annual Biotech in Europe Forum for Global Parntering & Investment, organised by Sachs Associates
Head of Belgian Biotech Firm Wins Business Worldwide Magazine CEO Award
August 23, 2023
London, United Kingdom
LONDON, Aug. 23, 2023 /PRNewswire/ -- In the 2023 Business Worldwide Magazine CEO Awards, Marc Dechamps, the CEO of Belgian biotech firm Bioxodes, receives an acknowledgment as he is named 'Biotechnology CEO of the Year - Europe'. Marc Dechamps was the outright winner in his category, for his ground-breaking work in the field of thrombo-inflammation or stroke.
ISTH 2023 Congress
June 26, 2023
Montréal, Canada
Bioxodes presented up-to-date preclinical data in intracerebral hemorrhage during the annual ISTH congress 2023 in Montréal.
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
All investors